source
- Tiziana's lower-dose foralumab cuts neuroinflammation in SPMS, but higher dose failsTiziana Life Sciences reported that its intranasal anti‑CD3 antibody, foralumab, lowered a neuroinflammation biomarker in patients with non‑active secondary progressive multiple sclerosis when give…
- FDA accepts first Keytruda biosimilar application as Merck faces looming patent cliffThe U.S. Food and Drug Administration has accepted the first publicly announced filing for a Keytruda biosimilar, identified as FYB206, which could receive approval as early as the third quarter of…